| Assay ID | Title | Year | Journal | Article |
|---|
| AID765734 | Binding affinity to human Eg5 D130V/A133D mutant at 500 uM by isothermal calorimetric analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID728342 | Growth inhibition of human K562 cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID725984 | Metabolic stability in mouse liver microsomes at 3 uM after 0.5 to 45 mins by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766268 | Inhibition of MT-stimulated ATPase activity of wild type Eg5 (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID766260 | Resistance factor, ratio of IC50 for Eg5 D130V mutant (unknown origin) to IC50 for wild type Eg5 (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID765742 | Inhibition of microtubule-stimulated ATPase activity of N-terminal His-6-tagged human wild type Eg5 (1 to 368) expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID726019 | Solubility of the compound in phosphate buffered saline at pH 2.0 after 2 hrs by turbidimetric analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID728336 | Growth inhibition of human HCT116 cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID765740 | Inhibition of microtubule-stimulated ATPase activity of human Eg5 D130V/A133D mutant expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID765746 | Inhibition of microtubule-stimulated ATPase activity of human Eg5 D130V mutant expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID765741 | Inhibition of microtubule-stimulated ATPase activity of human Eg5 A133D mutant expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID765738 | Binding affinity to human Eg5 D130V mutant at 250 uM by isothermal calorimetric analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID726004 | Inhibition of CYP2C19 (unknown origin) by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726001 | Inhibition of CYP2D6 (unknown origin) by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726021 | Growth inhibition of human BxPC3 cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766261 | Binding affinity to Eg5 D130V/A133D (unknown origin) by ITC study | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726008 | Drug recovery in 100% human plasma at 5 uM by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726022 | Growth inhibition of human NCI-H1299 cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID765737 | Resistance factor, ratio of IC50 for human Eg5 D130V mutant to IC50 for human wild type Eg5 | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID765736 | Resistance factor, ratio of IC50 for human Eg5 A133D mutant to IC50 for human Eg5 | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID725983 | Inhibition of MT-stimulated human N-terminal His6-tagged Eg5 (1 to 368 amino acid residues) motor domain ATPase activity expressed in Escherichia coli BL21 (DE3) by pyruvate kinase/lactate dehydrogenase-coupled assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID765735 | Binding affinity to human Eg5 A133D mutant at 250 uM by isothermal calorimetric analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID740544 | Toxicity in cancer patient administered as infusion for 1 hr every 21 days | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. |
| AID726006 | Inhibition of CYP1A2 (unknown origin) by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID765745 | Inhibition of microtubule-stimulated ATPase activity of N-terminal His-6-tagged human wild type Eg5 (1 to 368) expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID766264 | Binding affinity to wild type Eg5 (unknown origin) by ITC study | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726002 | Inhibition of CYP3A4 (unknown origin) by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726024 | Growth inhibition of human PC3 cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766265 | Partial inhibition of MT-stimulated ATPase activity of Eg5 D130V/A133D (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726014 | Distribution coefficient, log D of the compound in n-octanol buffer at pH 7.4 by shake flask method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726011 | Half life in human hepatocytes at 3 uM by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID765743 | Inhibition of microtubule-stimulated ATPase activity of human Eg5 D130V mutant expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID726005 | Inhibition of human ERG channel expressed in CHO cells by Ionworks HT assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726016 | Solubility of the compound in phosphate buffered saline at pH 7.4 after 2 hrs by turbidimetric analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726013 | Half life in human liver microsomes at 3 uM by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726020 | Solubility of the compound in phosphate buffered saline at pH 6.0 after 2 hrs by turbidimetric analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766267 | Inhibition of MT-stimulated ATPase activity of Eg5 D130V mutant (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726007 | Fraction unbound in 100% human plasma at 5 uM by equilibrium dialysis method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726018 | Dissociation constant, pKa of the compound by potentiometric method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766266 | Inhibition of MT-stimulated ATPase activity of Eg5 A133D mutant (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726003 | Inhibition of CYP2C9 (unknown origin) by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766259 | Resistance factor, ratio of IC50 for Eg5 A133D mutant (unknown origin) to IC50 for wild type Eg5 (unknown origin) | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID765739 | Binding affinity to human wild type Eg5 at 250 uM by isothermal calorimetric analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID766263 | Binding affinity to Eg5 D130V mutant (unknown origin) by ITC study | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID726015 | Intrinsic clearance in human liver microsomes assessed per mg of protein at 3 uM after 0.5 to 45 mins by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726017 | Partition coefficient, log P of the compound by potentiometric method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726023 | Growth inhibition of human LNCAP cells after 72 hrs by Alamar blue assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID726010 | Intrinsic clearance in human hepatocytes assessed per 10'6 cells at 3 uM after 1 to 60 mins by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. |
| AID766262 | Binding affinity to Eg5 A133D mutant (unknown origin) by ITC study | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Resistance by allostery: a novel perspective for eg5-targeted drug design. |
| AID765744 | Inhibition of microtubule-stimulated ATPase activity of human Eg5 A133D mutant expressed in Escherichia coli BL21 by pyruvate kinase/lactate dehydrogenase-linked assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |